

Disclaimer

This English translation is prepared by Marketing Authorization Holder.

The Japanese language package insert is the official document, and this translation is provided solely as a reference material. In the case of any discrepancy between the two versions, the original Japanese version prevails.

The provider of this translation shall not be responsible for any damage that may be attributed to the use of the translation.

This translation shall not be reproduced, reprinted or used for profit.

Since this translation is prepared in July 2025 based on the Japanese text current at that time, the translation may not reflect the latest information, due to continuous revision of package inserts.

The latest Japanese text is available on PMDA website.

# Kracie

Oct 2023 (1st version)

Standard Commodity Classification No. of Japan	
875200	
Approval No.	16100AMZ03517000
Date of Initial Marketing in Japan	Oct 1986

Kampo product

## Kracie Daisaikoto Extract Fine Granules

Storage : Store at room temperature  
Shelf Life : 3 years

KB-8

EK-8

### 3. COMPOSITION AND PRODUCT DESCRIPTION

#### 3.1 Composition

Brand name	Kracie Daisaikoto Extract Fine Granules	
Active ingredients	The daily dose of this product (6.0 g) contains 5,400 mg of JP Daisaikoto extract, derived from a mixture of the following crude drugs.	
	JP Bupleurum Root	6.0 g
	JP Pinellia Tuber	4.0 g
	JP Ginger	1.0 g
	JP Scutellaria Root	3.0 g
	JP Peony Root	3.0 g
	JP Jujube	3.0 g
	JP Immature Orange	2.0 g
JP Rhubarb	1.0 g	
Inactive ingredients	JP Magnesium Stearate, JP Light Anhydrous Silicic Acid, JP Microcrystalline Cellulose, Hydrated Silicon Dioxide	

(JP: The Japanese Pharmacopoeia)

#### 3.2 Product Description

Dosage form	Fine granules
Color	Light yellow-brown to brown
Odor	Characteristic odor
Taste	Slightly bitter
ID code	KB-8 (3.0 g per sachet)
	EK-8 (2.0 g per sachet)

### 4. INDICATIONS

The following symptoms in well-built, relatively physically strong patients with a tendency to constipation: Gastritis, habitual constipation, shoulder muscle stiffness/headache/constipation associated with hypertension, shoulder muscle stiffness, obesity

### 6. DOSAGE AND ADMINISTRATION

The usual adult dosage for oral use is 6.0 g daily in two or three divided doses before or between meals.

The dosage may be adjusted according to the patient's age, body weight, and symptoms.

### 8. IMPORTANT PRECAUTIONS

8.1 When this product is used, the patient's "SHO" (constitution/symptoms) should be taken into consideration. The patient's progress should be carefully monitored, and if no improvement in symptoms or findings is observed, continuous administration should be avoided.

8.2 When this product is used in combination with other Kampo products, etc., attention should be paid to the duplication of the contained crude drugs. Special attention should be paid to concomitant use with preparations containing Rhubarb.

8.3 Since there are individual differences in the cathartic action of Rhubarb, caution should be exercised with respect to dosage and administration.

### 9. PRECAUTIONS CONCERNING PATIENTS WITH SPECIFIC BACKGROUNDS

#### 9.1 Patients with Complication or History of Diseases, etc.

##### 9.1.1 Patients with diarrhea, loose stools

These symptoms may be aggravated.

##### 9.1.2 Patients with an extremely weak gastrointestinal tract

Anorexia, abdominal pain, diarrhea, etc. may occur.

##### 9.1.3 Patients with extremely weakened constitution

Adverse reactions are likely to occur, and the symptoms may be aggravated.

#### 9.5 Pregnant Women

It is not recommended to administer this product to pregnant women or women who may possibly be pregnant. There is a risk of premature birth or miscarriage due to the uterotonic action and hyperemic action of the pelvic organs of Rhubarb contained in this product.

#### 9.6 Breast-feeding Women

Considering the therapeutic benefits and the benefits of breastfeeding, continuation or discontinuation of breastfeeding should be considered. Anthraquinone derivatives in Rhubarb contained in this product are excreted in breast milk and may cause diarrhea in infants.

#### 9.7 Pediatric Use

No clinical studies have been conducted in children.

#### 9.8 Geriatric Use

Since the physiological functions are generally decreased in elderly patients, careful supervision is recommended; measures such as reducing the dose may be considered.

### 11. ADVERSE REACTIONS

The following adverse reactions may occur. Patients should be carefully monitored, and if any abnormalities are observed, appropriate measures such as discontinuation of administration should be taken.

#### 11.1 Clinically Significant Adverse Reactions

##### 11.1.1 Interstitial pneumonia (frequency unknown)

If cough, dyspnea, pyrexia, abnormal lung sound, etc. are observed, administration of this product should be discontinued, and examinations such as chest X-ray and chest CT scan should be performed immediately, and appropriate measures such as administration of corticosteroid should be taken. In addition, patients should be advised to discontinue administration of this product and contact the physician immediately if cough, dyspnea, or pyrexia, etc. occur.

##### 11.1.2 Hepatic impairment, jaundice (frequency unknown)

Hepatic impairment and/or jaundice with marked elevations of AST, ALT, Al-P, γ-GTP, etc. may occur.

#### 11.2 Other Adverse Reactions

	Frequency unknown
Gastrointestinal	Anorexia, Abdominal pain, Diarrhea, etc.

## **20. PRECAUTIONS FOR HANDLING**

**20.1** To maintain the quality of the product, avoid moisture as much as possible and store in a cool place, away from direct sunlight.

**20.2** Avoid moisture, especially after opening, and handle with care.

**20.3** Since this product is made from crude drugs, the color of the product may vary.

## **22. PACKAGING**

(KB-8)

3.0 g × 28 packets [sachets]

3.0 g × 168 packets [sachets]

(EK-8)

2.0 g × 42 packets [sachets]

2.0 g × 294 packets [sachets]

500 g [bottle]

## **26. MARKETING AUTHORIZATION HOLDER, etc.**

**26.1 Manufactured and Distributed by:**

***Kracie, Ltd.***

20-20, Kaigan 3-Chome, Minato-ku, Tokyo 108-8080, Japan

**26.2 Distributed by:**

***Kracie Pharmaceutical, Ltd.***

20-20, Kaigan 3-Chome, Minato-ku, Tokyo 108-8080, Japan